A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 378 participants.

Also called NCT07680829

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 378 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07680829
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07680829. Randomized; quadruple masking; primary purpose treatment. Start 2026-08 (anticipated); primary completion 2030-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia
Condition
Severe Hypertriglyceridemia
Intervention (Drug)
DR10624 Subcutaneous Injection
Intervention (Drug)
Icosapent Ethyl Oral Capsule
Intervention (Drug)
Matching Placebo Subcutaneous Injection
Lead sponsor
Zhejiang Doer Biologics Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07680829
Content hash
2c309794d06424a589cbde0e0690119c69aeea627f3acb3b4b28c8f2cc8400ab